Celldex Therapeutics, Inc. (CLDX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US15117B2025
Celldex Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.55 m USD |
| Gross profit | 1.35 m USD |
| Operating income | -287.37 m USD |
| EBIT | -258.76 m USD |
| Net income | -258.76 m USD |
| Diluted EPS – continuing operations | -3.90 USD |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
More stocks
- CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)
- PITNEY BOWES INC /DE/ (PBI)
- CPI Europe AG (CPI.VI)
- Premier Foods PLC (PFD.L)
- Zhejiang JIULI Hi-tech Metals Co Ltd (002318.SZ)
- Lakala Payment Co Ltd (300773.SZ)
- Bausch Health Companies Inc. (BHC)
- Bilfinger (GBF.DE)
- Ouster, Inc. (OUST)
- Beijing Ultrapower Software (300002.SZ)
- Kardex Holding AG (KARN.SW)
- Yantai Eddie Precision Mach (603638.SS)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.